文献速递认知障碍与痴呆

阿尔茨海默病试验中的靶点结合:Crenezumab降低脑脊液淀粉样β寡聚体水平

Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid.
PubMed 文献 · Ann Neurol · 2019-06-22

该研究开发超灵敏免疫分析法,检测104例AD受试者脑脊液中的oAβ,受试者来自crenezumab的ABBY和BLAZE 2期试验。结果显示,皮下和静脉给药组分别有89%和86%的患者第69周oAβ较基线降低,中位降幅为-48%和-43%,与安慰剂组差异显著。结论认为crenezumab降低了大多数治疗患者的脑脊液oAβ水平,支持靶点结合。

要点

  • Crenezumab治疗使大多数AD患者脑脊液oAβ水平较基线下降。
  • 皮下和静脉给药组oAβ降低比例均显著高于安慰剂组。
  • 脑脊液oAβ可作为抗Aβ药物试验的药效学生物标志物。

核心结论

  • Crenezumab在大多数受试AD患者中降低了脑脊液oAβ水平,支持其与AD主要病理靶点结合,并提示CSF oAβ可作为抗Aβ药物试验的新型药效学生物标志物。

研究设计与样本

  • 研究纳入参与crenezumab的ABBY和BLAZE 2期试验的104例AD受试者,使用超灵敏免疫分析法检测脑脊液oAβ。
  • 给药方案为皮下crenezumab 300mg或安慰剂每2周一次,或静脉crenezumab 15mg/kg或安慰剂每4周一次,持续68周。

主要发现

  • 皮下组89%、静脉组86%的患者第69周oAβ水平低于基线。
  • oAβ水平下降患者比例在皮下组(p=0.0035)和静脉组(p=0.01)均显著高于安慰剂组。
  • oAβ中位百分比变化为皮下组-48%、静脉组-43%。
  • 安慰剂组无系统性变化,中位变化为-13%,下降与上升患者比例相当。

临床怎么用

  • 结果支持在AD临床试验中将脑脊液oAβ作为抗Aβ治疗的药效学生物标志物。
  • Crenezumab的靶点结合证据可为抗Aβ药物剂量选择和机制验证提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Oligomeric forms of amyloid β protein (oAβ) are believed to be principally responsible for neurotoxicity in Alzheimer disease (AD), but it is not known whether anti-Aβ antibodies are capable of lowering oAβ levels in humans. METHODS: We developed an ultrasensitive immunoassay and used it to measure oAβ in cerebrospinal fluid (CSF) from 104 AD subjects participating in the ABBY and BLAZE phase 2 trials of the anti-Aβ antibody crenezumab. Patients received subcutaneous (SC) crenezumab (300mg) or placebo every 2 weeks, or intravenous (IV) crenezumab (15mg/kg) or placebo every 4 weeks for 68 weeks. Ninety-eight of the 104 patients had measurable baseline oAβ levels, and these were compared to levels at week 69 in placebo (n = 28), SC (n = 35), and IV (n = 35) treated patients. RESULTS: Among those receiving crenezumab, 89% of SC and 86% of IV patients had lower levels of oAβ at week 69 versus baseline. The difference in the proportion of patients with decreasing levels was significant for both treatment arms: p = 0.0035 for SC and p = 0.01 for IV crenezumab versus placebo. The median percentage change was -48% in the SC arm and -43% in the IV arm. No systematic change was observed in the placebo group, with a median change of -13% and equivalent portions with negative and positive change. INTERPRETATION: Crenezumab lowered CSF oAβ levels in the large majority of treated patients tested. These results support engagement of the principal pathobiological target in AD and identify CSF oAβ as a novel pharmacodynamic biomarker for use in trials of anti-Aβ agents. ANN NEUROL 2019;86:215-224.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Yang T, Dang Y, Ostaszewski B, et al. Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid. Ann Neurol. 2019. PMID: 31168802. doi:10.1002/ana.25513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。